Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
about
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cellsTertiary Lymphoid Organs in Cancer TissuesHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesVaccines for pancreatic cancerCurrent advances in immunotherapy for pancreatic cancerEvolution and dynamics of pancreatic cancer progressionSuppression, subversion and escape: the role of regulatory T cells in cancer progressionTargeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implicationsImmunotherapy as a Potential Treatment for Chordoma: a Review.Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in gliomaThe role of regulatory T cells in cancer.T cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model.Lymphocytes in cancer development: polarization towards pro-tumor immunityCancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma.Stromal reengineering to treat pancreas cancerImmunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationTumour-infiltrating T-cell subpopulations in glioblastomas.SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling.Complex role for the immune system in initiation and progression of pancreatic cancer.FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasisAccumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cellsThe prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survivalExpression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance.Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patientsPancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study.Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancerArginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancerControl of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers.A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation
P2860
Q24681974-6EEE09F9-F6F3-4C31-9D09-BD00E1D721EAQ26742168-01943A5F-F27D-430D-B178-19EC64077D52Q26747695-E4FFFCF6-CC10-4396-9D67-5AA2BF0D17B2Q26777542-662133BD-642B-4998-AAEA-B148F955A197Q26781538-70621DCC-9399-44E8-AC74-DFB5EB31BAC1Q26799714-206F76D5-5059-4C2F-8FFF-951EFD7A373CQ26825850-D070632A-BFAC-44B9-9E7E-6B61CEFAC6F5Q26830170-679DA6C5-7DAC-49DF-A09C-C5837F0AE948Q26849671-EACA76E7-4203-4F80-B23A-291C61F1CA1BQ27026151-AA05E0DB-6111-44E7-834E-C647FC66CF9AQ28269990-C69B8E38-2040-4CC5-8EE1-426B9964D0C9Q33276143-2A283B63-7C60-4CAB-968E-3F5491800BEEQ33560501-AC40A227-2F81-4372-BCAB-5E5AAF1F6BCCQ33567742-DED313CE-6231-4AD9-8A4C-0AB530B41313Q33589487-BAF78F1E-695E-49A0-90AC-E9269C67144AQ33613584-AD4E877C-B546-4917-BD03-15620BF02927Q33631986-1FB6CAE5-1A9F-4E29-9CCF-78E420EEAA29Q33685236-B353D4CB-C8B1-4535-B4AB-CF7374644398Q33712435-D651DD0E-1097-4C4A-9B23-5CD7B54299B1Q33753714-74CC1F26-9124-43C6-9069-A26519658BA8Q33827708-09A519D3-B263-4C19-AFCD-92B14448E881Q33848077-1D09D820-6318-4D9E-8CEA-323106F46D48Q33943553-8CCB4AB4-FEB4-4B96-BD95-51914D0AA19FQ33983083-33DD843B-D2BE-4A00-8CD8-79BA9E2CD794Q33987977-01DCED85-816C-413E-9831-0B0ACDBE406AQ34079557-894FE9A5-FE22-41A4-9A21-438EA3798E8DQ34093784-FB2B5E2C-7851-4B55-A1C5-8D1EFAA3DC53Q34142307-C3992F06-E51E-4086-8242-435B49070571Q34154623-2C89E388-6AB3-452A-B86B-2F56C67C51E8Q34188723-8587C1A5-F136-46B7-9C2B-7CE15DF68A07Q34269713-5F7B4233-4AFF-4422-8425-486784BB3713Q34354653-6B2F2C53-F496-4AC8-93C9-A79560A94AB5Q34431614-31805F65-27AF-4002-AC35-10AC08A1F467Q34486464-82AD5E23-E94A-43CE-876E-981389A68E7AQ34538321-9C838847-4483-4BF6-85E1-2DDE4E88A2FDQ34566554-8AAA87B1-6B7E-4D70-9E7E-48C19E5B471EQ34575227-C2881C33-10F9-44B1-92D7-CE57F6C39C2AQ34592559-B46CE7F2-16C2-4520-9D73-EC1ECBF7AB51Q34708248-9A202F21-F28D-4370-AD79-F03B55B83567Q34904065-0CFED6C3-4AD3-421F-BA0E-CC84DA4E3E0A
P2860
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@en
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@nl
type
label
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@en
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@nl
prefLabel
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@en
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@nl
P2093
P1476
Prevalence of FOXP3+ regulator ...... and its premalignant lesions.
@en
P2093
Kaoru Onozato
Nobuyoshi Hiraoka
Setsuo Hirohashi
Tomoo Kosuge
P304
P356
10.1158/1078-0432.CCR-06-0369
P407
P577
2006-09-01T00:00:00Z